Physiomics (PYC) Competitors GBX 0.40 -0.03 (-5.81%) As of 11:28 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock PYC vs. EVG, MTFB, DEST, ROQ, VAL, RENE, BSFA, SALV, OVB, and ONCShould you be buying Physiomics stock or one of its competitors? The main competitors of Physiomics include Evgen Pharma (EVG), Motif Bio (MTFB), Destiny Pharma (DEST), Roquefort Therapeutics (ROQ), ValiRx (VAL), ReNeuron Group (RENE), BSF Enterprise (BSFA), SalvaRx Group (SALV), Ovoca Bio (OVB), and Oncimmune (ONC). These companies are all part of the "biotechnology" industry. Physiomics vs. Evgen Pharma Motif Bio Destiny Pharma Roquefort Therapeutics ValiRx ReNeuron Group BSF Enterprise SalvaRx Group Ovoca Bio Oncimmune Evgen Pharma (LON:EVG) and Physiomics (LON:PYC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation. Do insiders & institutionals hold more shares of EVG or PYC? 27.8% of Evgen Pharma shares are owned by institutional investors. 32.4% of Evgen Pharma shares are owned by insiders. Comparatively, 4.2% of Physiomics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, EVG or PYC? Evgen Pharma has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Physiomics has a beta of 1.69, meaning that its share price is 69% more volatile than the S&P 500. Does the MarketBeat Community favor EVG or PYC? Evgen Pharma received 113 more outperform votes than Physiomics when rated by MarketBeat users. Likewise, 74.23% of users gave Evgen Pharma an outperform vote while only 55.56% of users gave Physiomics an outperform vote. CompanyUnderperformOutperformEvgen PharmaOutperform Votes19374.23% Underperform Votes6725.77% PhysiomicsOutperform Votes8055.56% Underperform Votes6444.44% Does the media favor EVG or PYC? In the previous week, Evgen Pharma had 1 more articles in the media than Physiomics. MarketBeat recorded 1 mentions for Evgen Pharma and 0 mentions for Physiomics. Physiomics' average media sentiment score of 0.00 beat Evgen Pharma's score of -0.84 indicating that Physiomics is being referred to more favorably in the news media. Company Overall Sentiment Evgen Pharma Negative Physiomics Neutral Is EVG or PYC more profitable? Evgen Pharma has a net margin of 0.00% compared to Physiomics' net margin of -106.80%. Evgen Pharma's return on equity of -60.57% beat Physiomics' return on equity.Company Net Margins Return on Equity Return on Assets Evgen PharmaN/A -60.57% -45.52% Physiomics -106.80%-127.68%-76.38% Which has better valuation and earnings, EVG or PYC? Physiomics has higher revenue and earnings than Evgen Pharma. Physiomics is trading at a lower price-to-earnings ratio than Evgen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvgen PharmaN/AN/A-£3.35M-£0.01N/APhysiomics£864.07K0.96-£922.82K-£0.45-0.91 SummaryEvgen Pharma beats Physiomics on 9 of the 14 factors compared between the two stocks. Remove Ads Get Physiomics News Delivered to You Automatically Sign up to receive the latest news and ratings for PYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYC vs. The Competition Export to ExcelMetricPhysiomicsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£831,000.00£107.79M£5.59B£2.57BDividend Yield6.20%3.78%5.37%4.95%P/E Ratio-0.913.1023.59140.01Price / Sales0.964,194.85371.05262,597.18Price / Cash4.2112.7538.1727.90Price / Book1.9435.776.674.53Net Income-£922,817.80-£91.48M£3.20B£5.76B7 Day Performance-6.03%-4.22%-5.58%0.34%1 Month Performance-15.63%58.78%-0.75%5.74%1 Year Performance-68.85%82.71%7.88%107.79% Physiomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYCPhysiomicsN/AGBX 0.41-5.8%N/A-67.7%£831,000.00£864,071.75-0.9110Gap DownEVGEvgen PharmaN/AN/AN/AN/A£3.42MN/A-80.0010MTFBMotif BioN/AN/AN/AN/A£3.28MN/A-0.036DESTDestiny PharmaN/AN/AN/AN/A£2.87M£135,028.00-50.0024Gap DownHigh Trading VolumeROQRoquefort TherapeuticsN/AGBX 1.87-1.8%N/A-77.1%£2.37M£2,662.35-1.549High Trading VolumeVALValiRxN/AGBX 0.60+4.3%N/A-84.8%£2.28M£27,777.32-0.405,450Gap UpRENEReNeuron GroupN/AN/AN/AN/A£1.93M£783,000.00-37.502Gap DownBSFABSF EnterpriseN/AGBX 1.50+9.1%N/A-72.9%£1.85M£80,250.74-0.9112Gap UpSALVSalvaRx GroupN/AN/AN/AN/A£1.65M£64.50M0.032Gap UpOVBOvoca BioN/AGBX 1.40flatN/A+92.9%£1.41MN/A-1.295ONCOncimmuneN/AGBX 1.14flatN/AN/A£1.29M£1.86M0.1352Negative News Remove Ads Related Companies and Tools Related Companies Evgen Pharma Competitors Motif Bio Competitors Destiny Pharma Competitors Roquefort Therapeutics Competitors ValiRx Competitors ReNeuron Group Competitors BSF Enterprise Competitors SalvaRx Group Competitors Ovoca Bio Competitors Oncimmune Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:PYC) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredNew Pick (93% history of rising by May 8)We just posted a new recommendation. Keep in mind: You could have boosted the Netflix trade we issued to the p...InvestorPlace | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Physiomics Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Physiomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.